首页> 美国卫生研究院文献>Lippincott Williams Wilkins Open Access >Safety Tolerability and Pharmacokinetics of MEDI8897 an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

【2h】

Safety Tolerability and Pharmacokinetics of MEDI8897 an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

机译：MEDI8897的安全性耐受性和药代动力学这是一种延长剂量的针对健康早产婴儿的半衰期单剂量呼吸道合胞病毒预融合F靶向单克隆抗体

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:MEDI8897 is a recombinant human monoclonal antibody being developed for prophylaxis of serious respiratory syncytial virus (RSV) disease in all infants.

机译：背景：MEDI8897是一种重组人单克隆抗体，正在开发中，用于预防所有婴儿中的严重呼吸道合胞病毒（RSV）疾病。

著录项

期刊名称 Lippincott Williams Wilkins Open Access
作者
Joseph B. Domachowske; Anis A. Khan; Mark T. Esser; Kathryn Jensen; Therese Takas; Tonya Villafana; Filip Dubovsky; M. Pamela Griffin;
展开▼
作者单位

展开▼
年(卷),期 -1(37),9
年度 -1
页码 886–892
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
infants lower respiratory tract infections MEDI8897 preterm infants respiratory syncytial virus;

机译：婴儿;下呼吸道感染;MEDI8897;早产儿;呼吸道合胞病毒;

相似文献

外文文献
中文文献

1. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [J] . Domachowske Joseph B., Khan Anis A., Esser Mark T., The Pediatric infectious disease journal . 2018 ,第9期

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康的早产儿
2. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [J] . Domachowske Joseph B., Khan Anis A., Esser Mark T., The Pediatric infectious disease journal . 2018 ,第9期

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康的早产儿
3. Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV) [J] . Pierre Vadryn, Griffin M. Pamela, Shoemaker Kathryn, Journal of pharmacokinetics and pharmacodynamics . 2018 ,第Suppla期

机译：Medi8897的人口药代动力学建模，延长半衰期单克隆抗体（MAB），以及预料和全初期婴儿的剂量预测，以防止呼吸合胞病毒（RSV）引起的呼吸道感染
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Safety Tolerability and Pharmacokinetics of MEDI8897 the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life in Healthy Adults [O] . M. Pamela Griffin, Anis A. Khan, Mark T. Esser, 2017

机译：健康成人的呼吸道合胞病毒预融合F靶向单克隆抗体MEDI8897的安全性耐受性和药代动力学具有延长的半衰期
6. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [O] . Joseph B. Domachowske, Anis A. Khan, Mark T. Esser, 2018

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康早产儿

Safety Tolerability and Pharmacokinetics of MEDI8897 an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

摘要

著录项

相似文献

相关主题

期刊订阅